Sarang Deo, Professor of Operations Management and Executive Director of the Max Institute of Healthcare Management and Deputy Dean for Faculty & Research, Indian School of Business
- Pete Baker, Deputy Director and Policy Fellow, Center for Global Development
- David Blazes, Deputy Director, Vaccine Development & Surveillance – Modelling and Pathogen Genomic Sequencing, Gates Foundation
- Josefina Campos, Senior Technical Advisor to the International Pathogen Surveillance Network, World Health Organization Hub for Pandemic and Epidemic Intelligence
Javier Guzman, Senior Policy Fellow and Director of Global Health, Center for Global Development
The COVID-19 pandemic highlighted the benefits of whole-genomic sequencing (WGS) surveillance systems. However, investment in genomic surveillance in low- and middle-income countries has been relatively low, as the benefits are often abstract and difficult to quantify.
With the Pandemic Fund having selected its first round of projects, and as countries decide how to strengthen their pandemic preparedness and response (PPR) systems, what are the costs and benefits of implementing WGS surveillance systems in low- and middle-income countries? And what level of priority should WGS surveillance systems be given compared to other PPR interventions?
New research from the Indian School of Business (Max Institute of Healthcare Management) and CGD has assessed the cost-effectiveness of genomic surveillance in India. This event dives into the results of the new research and explores the wider implications of WGS on pandemic preparedness, prevention, and mitigation response efforts in low- and middle-income countries.